Search

Displaying results 2101 - 2110 of 9313 in total
  1. Drug

    Neostigmine

    go.drugbank.com/drugs/DB01400
    ApprovedInvestigationalVet approved

    A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. … Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.

    Products: NEOSTIGMINA METILSULFATO SOLUCION INYECTABLE DE 0.5 MG / 1 ML.
  2. Drug

    Mecamylamine

    go.drugbank.com/drugs/DB00657
    ApprovedInvestigational

    A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier.

  3. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254941] However, the development of KRAS inhibitors has been challenging due to their high affinity for guanosine triphosphate (GTP) and guanosine diphosphate (GDP), as well as the lack of a clear binding … [L43847] In December 2022, the FDA granted accelerated approval to adagrasib for the treatment of KRAS<sup>G12C</sup>-mutated locally advanced or metastatic NSCLC who have received at least one prior systemic

  4. Drug

    Rofecoxib

    go.drugbank.com/drugs/DB00533
    ApprovedWithdrawn

    Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. … This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety.

  5. Drug

    Calcifediol

    go.drugbank.com/drugs/DB00146
    ApprovedInvestigationalNutraceutical

    The major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. … It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.

    Synonyms: (3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol, (3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-3,25-diolInternational brands: De Kai
  6. Drug

    Deoxycholic acid

    go.drugbank.com/drugs/DB03619
    ApprovedInvestigational

    In April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical

  7. Drug

    Probucol

    go.drugbank.com/drugs/DB01599
    ApprovedInvestigationalWithdrawn

    A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).

  8. Drug

    Sacituzumab govitecan

    go.drugbank.com/drugs/DB12893
    ApprovedInvestigational

    approval for the treatment of mTNBC patients who have undergone two or more prior therapies. … As a targeted cytotoxic agent, it is hoped to provide similar efficacy with reduced adverse effects.

  9. Drug

    Aspergillus repens

    go.drugbank.com/drugs/DB10449
    Approved

    Aspergillus repens is a fungus which can provoke allergic reactions. Aspergillus repens extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  10. Drug

    Durlobactam

    go.drugbank.com/drugs/DB16704
    ApprovedInvestigational

    [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. … It is typically given in combination with [sulbactam] to protect it from degradation by certain serine-beta-lactamases.